A European multicentre PET study of fibrillar amyloid in Alzheimer's disease

: Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, Perani D, Forsberg A, Langstrom B, Scheinin N, Karrasch M, Nagren K, Grimmer T, Miederer I, Edison P, Okello A, Van Laere K, Nelissen N, Vandenbulcke M, Garibotto V, Almkvist O, Kalbe E, Hinz R, Herholz K

Publisher: SPRINGER

: 2013

: European Journal of Nuclear Medicine and Molecular Imaging

: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

: EUR J NUCL MED MOL I

: 1

: 40

: 1

: 104

: 114

: 11

: 1619-7070

DOI: https://doi.org/10.1007/s00259-012-2237-2

This study demonstrated the robustness of [C-11]PIB PET as a marker of neocortical fibrillar amyloid deposition in brain when assessed in a multicentre setting. MCI PIB-positive patients showed more severe memory impairment than MCI PIB-negative patients and progressed to AD at an estimated rate of 25 % per year. None of the MCI PIB-negative patients converted to AD, and thus PIB negativity had a 100 % negative predictive value for progression to AD. This supports the notion that PIB-positive scans in MCI patients are an indicator of prodromal AD.